Engineering Breast Cancer Cells for Self-destruction

Self-destruction is a novel immunotherapeutic strategy for exploiting cancer cells against themselves. This strategy uses different technologies or assays to engineer breast cancer cells to achieve cytokines overexpression and to assess the effect of self-destruction by different assays. Creative Biolabs offers state-of-the-art services for engineering breast cancer cell lines for self-destruction that meet your specific tumor research needs.

Background of Breast Cancer

Breast cancer is by far the most frequent type of cancer affecting women and a leading cause of death, despite advances in its detection and treatment. There are different forms of breast cancer and the causes are just as varied. One reason for the development of cancer, among others, is that cells that have accumulated defects have lost the ability to destroy themselves.

Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumor grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modeled using established cell lines.

Table.1 Molecular classification of breast carcinoma. (Holliday, 2011)

Classification	Immunoprofile	Other Characteristics	Example Cell Lines
Luminal A	ER⁺, PR^+/-, HER2^-	Ki67 low, endocrine responsive, often chemotherapy responsive	MCF-7, T47D, SUM185
Lyminal B	ER⁺, PR^+/-, HER2⁺	Ki67 high, usually endocrine responsive, variable to chemotherapy. HER2⁺ are trastusumab responsive	BT474, ZR-75
Basal	ER^-, PR^-, HER2^-	EGFR⁺ and/or cytokeratin 5/6⁺, Ki67 high, endocrine nonresponsive, often chemotherapy responsive	MDA-MB-468, SUM190
Claudin-low	ER⁺, PR^-, HER2^-	Ki67, E-cadherin, claudin-3, claudinin-4 and claudinin-7 low. Intermediate response to chemotherapy	BT549, MDA-MB-231, Hs578T, SUM1315
HER2	ER⁺, PR^-, HER2⁺	Ki67 high, trastusumab responsive, chemotherapy responsive	SKBR3, MDA-MB-453

Main Cell Lines for Engineering in Breast Cancer Research

MCF7
The exquisite hormone sensitivity of MCF-7 through expression of estrogen receptor (ER), making it an ideal breast cancer model to study hormone response.

MDA-MB-468
MDA-MB-468 is a cell line commonly used in breast cancer research. It was extracted from a pleural effusion of mammary gland and breast tissues, and have proven useful for the study of metastasis, migration, and breast cancer proliferation.

HCC1937
HCC1937 was isolated from a primary carcinoma of a germ-line BRCA1 mutation carrier.

Our Service

Creative Biolabs has extensive experience in breast cancer cell models and breast cancer immunobiology. We offer a full-scale range of self-destruction services to meet your scientific needs. Below is a workflow of our engineering cancer cell for self-destruct strategy.

Fig.1 Workflow of engineering breast cancer cells for self-destruction. (Creative Biolabs)

With a team of scientists who come from different research backgrounds, Creative Biolabs guides you all the way from project inception to high-quality results. For more cancer cell lines for self-destruction, please visit the unit of Engineering Cancer Cells for Self-destruction. If you have interest, please do not hesitate to contact us.

Reference

Holliday, D.L.; et al. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011, 12;13(4): 215.

For Research Use Only | Not For Clinical Use